Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response dura ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

A 74-year-old man, diagnosed with advanced kidney cancer and facing an 80% damaged kidney, opted for natural treatment at ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

Investing.com -- Exelixis Inc. (NASDAQ:EXEL) shares fell 6.6% Monday after Merck announced its combination therapy outperformed Exelixis’ monotherapy Cabometyx in a late-stage kidney cancer trial.

Dutch-Turkish rapper Yukkie B, born Yuksel Ozince, died Sunday at the age of 56 from kidney cancer, his former partner ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

Findings presented at the 2026 ASCO GU Symposium show that combinatorial therapies may provide new treatment options for ...